Zenas Bio Pharma, Inc. ZBIO
We take great care to ensure that the data presented and summarized in this overview for Zenas BioPharma, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ZBIO
Top Purchases
Top Sells
About ZBIO
Insider Transactions at ZBIO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 04
2024
|
Leon O Moulder Jr Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
45,000
+15.73%
|
$405,000
$9.98 P/Share
|
|
Dec 03
2024
|
Leon O Moulder Jr Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
25,000
+11.3%
|
$250,000
$10.76 P/Share
|
|
Nov 19
2024
|
Leon O Moulder Jr Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,500
+1.44%
|
$35,000
$14.57 P/Share
|
|
Nov 18
2024
|
Leon O Moulder Jr Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
7,500
+4.26%
|
$112,500
$15.0 P/Share
|
|
Sep 20
2024
|
Leon O Moulder Jr Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
5,000
+0.15%
|
$90,000
$18.42 P/Share
|
|
Sep 19
2024
|
Leon O Moulder Jr Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
5,000
+0.3%
|
$85,000
$17.89 P/Share
|
|
Sep 18
2024
|
Leon O Moulder Jr Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
10,000
+0.6%
|
$170,000
$17.91 P/Share
|
|
Sep 16
2024
|
Wellington Biomedical Innovation Master Investors (Cayman) I L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
801,624
+37.06%
|
-
|
|
Sep 16
2024
|
Enavate Sciences Gp, LLC |
BUY
Open market or private purchase
|
Indirect |
882,353
+19.0%
|
$15,000,001
$17.0 P/Share
|
|
Sep 16
2024
|
Enavate Sciences Gp, LLC |
BUY
Conversion of derivative security
|
Indirect |
2,879,006
+50.0%
|
-
|
|
Sep 16
2024
|
Jason Raleigh Nunn |
BUY
Open market or private purchase
|
Indirect |
882,352
+23.46%
|
$14,999,984
$17.0 P/Share
|
|
Sep 16
2024
|
Jason Raleigh Nunn |
BUY
Conversion of derivative security
|
Indirect |
2,174,449
+50.0%
|
-
|
|
Sep 16
2024
|
Patrick G Enright Director |
BUY
Open market or private purchase
|
Indirect |
440,000
+36.23%
|
$7,480,000
$17.0 P/Share
|
|
Sep 16
2024
|
Patrick G Enright Director |
BUY
Conversion of derivative security
|
Indirect |
2,061,934
+45.58%
|
-
|
|
Sep 16
2024
|
Sr One Capital Management, LLC |
BUY
Open market or private purchase
|
Indirect |
2,235,294
+29.7%
|
$37,999,998
$17.0 P/Share
|
|
Sep 16
2024
|
Sr One Capital Management, LLC |
BUY
Conversion of derivative security
|
Indirect |
2,676,245
+50.0%
|
-
|
|
Sep 16
2024
|
Fairmount Funds Management LLC Director |
BUY
Open market or private purchase
|
Indirect |
300,000
+15.75%
|
$5,100,000
$17.0 P/Share
|
|
Sep 16
2024
|
Fairmount Funds Management LLC Director |
BUY
Conversion of derivative security
|
Indirect |
1,304,891
+39.1%
|
-
|
|
Sep 16
2024
|
Leon O Moulder Jr Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
156,635
+36.78%
|
-
|
|
Sep 16
2024
|
Leon O Moulder Jr Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
536,540
+45.47%
|
-
|
Last 12 Months Summary
Buy / Acquisition
17.5M
Shares
From
14
Insiders
| Open market or private purchase | 4.9M shares |
|---|---|
| Conversion of derivative security | 12.6M shares |
Sell / Disposition
0
Shares
From
0
Insiders